基本信息
浏览量:170
职业迁徙
个人简介
My main interests are cancer biology and therapeutics. Over the last 20 years, I have been working on quite a few strategies to treat cancer in animal models. These include gene therapy, immunotherapy, epigenetic therapy and oncolytic virotherapy.
Once a patient is diagnosed with cancer, the standard treatments are surgery if it is resectable, then radiotherapy and/or chemotherapy may follow. Depending on the type and stage of cancer, the patients can be undergoing with other adjuvant therapies (pharmacological or immunological agents). If everything fails, the he/she may be treated with experimental biological therapies (immunotherapy, gene therapy and oncolytic virotherapy). Some of these have been recently approved for clinical use, such as two adenoviruses (in China), and a cancer vaccine, sipuleucel-T (Provenge®), for advanced prostate cancer approved by FDA. Three oncolytic viruses are undergoing phase III clinical trials in the world and may become approved drugs in the near future.
My group has been working hard to elucidate the mechanisms of novel agents (viruses and epigenetic drugs) to inhibit cancer in vitro and in animal models. Some viruses are being tested in cancer patients.
Once a patient is diagnosed with cancer, the standard treatments are surgery if it is resectable, then radiotherapy and/or chemotherapy may follow. Depending on the type and stage of cancer, the patients can be undergoing with other adjuvant therapies (pharmacological or immunological agents). If everything fails, the he/she may be treated with experimental biological therapies (immunotherapy, gene therapy and oncolytic virotherapy). Some of these have been recently approved for clinical use, such as two adenoviruses (in China), and a cancer vaccine, sipuleucel-T (Provenge®), for advanced prostate cancer approved by FDA. Three oncolytic viruses are undergoing phase III clinical trials in the world and may become approved drugs in the near future.
My group has been working hard to elucidate the mechanisms of novel agents (viruses and epigenetic drugs) to inhibit cancer in vitro and in animal models. Some viruses are being tested in cancer patients.
研究兴趣
论文共 128 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
MOLECULAR THERAPYno. 11 (2023): 3112-3114
crossref(2023)
Clinical and translational discoveryno. 2 (2022): n/a-n/a
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn